Compare GOVX & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOVX | DRCT |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | 17 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 8.9M |
| IPO Year | N/A | 2022 |
| Metric | GOVX | DRCT |
|---|---|---|
| Price | $0.22 | $0.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.00 | $6.00 |
| AVG Volume (30 Days) | 4.1M | ★ 25.1M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,353,560.00 | ★ $35,369,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.52 | N/A |
| 52 Week Low | $0.12 | $0.05 |
| 52 Week High | $2.71 | $2.61 |
| Indicator | GOVX | DRCT |
|---|---|---|
| Relative Strength Index (RSI) | 39.34 | 28.65 |
| Support Level | $0.16 | $0.05 |
| Resistance Level | $0.21 | $0.08 |
| Average True Range (ATR) | 0.04 | 0.01 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 46.55 | 11.18 |
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.